If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
BioProcess
International
DIGITAL EDITION
ARCHIVE
New antibody
formats on
the block
Biopharma researchers developing inno-
vative target molecules rely on safe and
HIˉFLHQWSXULˉFDWLRQSURFHVVHVDQGFORVH
collaboration with Tosoh Bioscience.
#ChromatographyExperts
New Antibody Formats on the Block
More Complex Modalities Demand Innovation in Manufacturing and Purification
Romain Dabre
O
ver the past 15 years, monoclonal antibodies (MAbs)
have dominated the biopharmaceutical market, but
now alternative antibody formats are emerging and
moving through company pipelines. These include MAb
fragments, single-chain fragment antibodies, and modified
antibodies — e.g., antibody–drug conjugates (ADCs),
engineered antibodies, and bispecific antibodies.
For conventional MAbs, drug companies
BioProcess International DIGITAL EDITION ARCHIVE
New antibody formats on the block Biopharma rese
New Antibody Formats on the Block More Complex M
Improved Capture of Antibody Fragments Romain D
Figure 1: Chromatograms of the protein L capture
Figure 4: Pressure-flow curve for Toyopearl AF-rP
Efficient Biopharmaceutical Partnerships A Key t
Other essential factors include guaranteed delive
#CHROMATO GRAPHY EXPERTS Efficiently purify an